🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Pancreatic Ductal Adenocarcinoma (PDAC)

A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance NCT07483983Phase 27 sites📍 Villejuif📍 Bordeaux📍 Dijon Gustave Roussy, Cancer Campus, Grand Paris · Tests: ASP3082 A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers NCT07769502Phase 27 sites📍 Hattiesburg📍 Ramat Gan📍 Jerusalem AbbVie · Tests: Telisotuzumab Adizutecan, Gemcitabine, Nab-Paclitaxel PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma NCT07047807NA1 site📍 Boston Massachusetts General Hospital · Tests: PDAC-PATHWAYS, Usual Care PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017Phase 19 sites📍 Newport Beach📍 Miami📍 Detroit PanTher Therapeutics · Tests: PTM-101 A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896EARLY Phase 12 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Screening Blood Tests, Endoscopic Ultrasound, Magnetic Resonance Imaging, Magnetic Resonance Cholangiopancreatography Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer NCT06782932Phase 1, Phase 21 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: AGEN2373, Balstilimab, Cyclophosphamide, GVAX, AGEN2373 (RP2D) Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT06895031Phase 21 site📍 Beijing Guangzhou JOYO Pharma Co., Ltd · Tests: JYP0015 Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445Phase 382 sites📍 Phoenix📍 Scottsdale📍 Los Angeles Revolution Medicines, Inc. · Tests: daraxonrasib, gemcitabine, nab-paclitaxel Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631Phase 19 sites📍 Princeton📍 Montreal📍 Odense C Novartis Pharmaceuticals · Tests: 68Ga-NNS309, 177Lu-DFC413 BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma NCT07259317Phase 220 sites📍 Scottsdale📍 Los Angeles📍 Orange Corcept Therapeutics · Tests: Relacorilant, Nab-paclitaxel, Gemcitabine Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC NCT07155850NA2 sites📍 Roma📍 London BetaGlue Therapeutics SpA · Tests: Medical device containing Y-90 microspheres delivered intratumorally and percutaneously into the pancreas Nutrition Intervention for Pancreatic Cancer NCT07554560NA2 sites📍 Philadelphia📍 Philadelphia Children's Hospital of Philadelphia · Tests: Structured Lipid Medical Food A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) NCT05472259Phase 213 sites📍 Antwerp📍 Brussels📍 Brussels Belgian Group of Digestive Oncology · Tests: Nanoliposomal irinotecan, 5 FU, Leucovorin, Oxaliplatin Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer NCT05218889Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer NCT07683845n/a1 site📍 Shanghai Beijing Daxiang Biotech Co., Ltd Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB) NCT06666803NA2 sites📍 Strasbourg📍 Strasbourg IHU Strasbourg · Tests: FNB sampling, blood sampling Monitoring and Managing Glucose Levels in People With Pancreatic Cancer NCT05132244NA2 sites📍 Vancouver📍 Toronto British Columbia Cancer Agency · Tests: Glucose Measurements via Blood Draw Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens NCT07542041NA1 site📍 Tampa ARTIDIS AG · Tests: ARTIDIS ART-1 Device Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT07435038Phase 1, Phase 27 sites📍 Blacktown📍 Randwick📍 Sydney Betta Pharmaceuticals Co., Ltd. · Tests: BPI-572270 AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055Phase 1, Phase 24 sites📍 El Segundo📍 Summit📍 New York Engeneic Pty Limited · Tests: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy